Back to Journals » OncoTargets and Therapy » Volume 6
Accumulation of p62 is associated with poor prognosis in patients with triple-negative breast cancer
Authors Luo R, Yuan Z, Li M, Xi S, Fu J, He J
Received 4 April 2013
Accepted for publication 2 May 2013
Published 19 July 2013 Volume 2013:6 Pages 883—888
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Rong-Zhen Luo,1,2,* Zhong-Yu Yuan,1,3,* Mei Li,1,2 Shao-Yan Xi,1,2 Jia Fu,1,2 Jiehua He1,2
1State Key Laboratory of Oncology in South China, 2Department of Pathology, 3Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China
*These authors contributed equally to this work
Background: Triple-negative breast cancer (TNBC) is associated with poor prognosis. There is an urgent need for elucidation of novel targets for TNBC therapy and to improve the prognosis of patients. The aim of this study was to evaluate the prognostic value of p62 expression in TNBC.
Methods and results: Expression of p62 in tissue microarray was evaluated by immunohistochemistry in 163 patients with TNBC. The prognostic value of p62 expression was assessed by a Cox regression model adjusted for clinical characteristics. Overexpression of p62 was observed in 51 (31.3%) of 163 TNBC, and significantly correlated with advanced stage and a higher proportion of positive lymph nodes and lymphovascular invasion. A significant correlation was found between p62 expression and disease-free survival and overall survival. Accordingly, the 10-year distant metastasis-free survival for p62-overexpression and p62-underexpression patients were 58.9% and 92.5%, respectively (P<0.0001). Multivariate analysis indicated that p62-negative was a significant independent prognostic factor of disease-free survival (P=0.017), but not for overall survival (P=0.845) in all patients.
Conclusion: Our results suggest that overexpression of p62 in TNBC is associated with a higher risk of distant metastases. This finding could open new avenues for the development of novel therapy strategies for TNBC.
Keywords: triple-negative breast cancer, p62, prognosis, tissue microarrays
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.